PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
Oct 1, 2018, 00:00
10.1016/j.jval.2018.09.176
https://www.valueinhealthjournal.com/article/S1098-3015(18)33476-4/fulltext
Title :
PCN94 - COST-EFFECTIVENESS OF CABOZANTINIB VERSUS SUNITINIB OR PAZOPANIB AS FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED RENAL CELL CARCINOMA IN THE UK
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33476-4&doi=10.1016/j.jval.2018.09.176
First page :
Section Title :
Open access? :
No
Section Order :
1154